NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria

Cerebral malaria (CM) is the severe progression of an infection with <i>Plasmodium falciparum</i>, causing detrimental damage to brain tissue and is the most frequent cause of <i>Plasmodium falciparum</i> mortality. The critical role of brain-infiltrating CD8<sup>+</...

Full description

Saved in:
Bibliographic Details
Main Authors: Victoria E. Stefan, Victoria Klepsch, Nikolaus Thuille, Martina Steinlechner, Sebastian Peer, Kerstin Siegmund, Peter Lackner, Erich Schmutzhard, Karin Albrecht-Schgör, Gottfried Baier
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/14/15/1162
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cerebral malaria (CM) is the severe progression of an infection with <i>Plasmodium falciparum</i>, causing detrimental damage to brain tissue and is the most frequent cause of <i>Plasmodium falciparum</i> mortality. The critical role of brain-infiltrating CD8<sup>+</sup> T cells in the pathophysiology of CM having been revealed, our investigation focuses on the role of NR2F6, an established immune checkpoint, as a candidate driver of CM pathology. We employed an experimental mouse model of CM based on <i>Plasmodium berghei</i> ANKA (<i>PbA</i>) infection to compare the relative susceptibility of <i>Nr2f6</i>-knock-out and wild-type C57BL6/N mice. As a remarkable result, <i>Nr2f6</i> deficiency confers a significant survival benefit. In terms of mechanism, we detected less severe endotheliopathy and, hence, less damage to the blood–brain barrier (BBB), accompanied by decreased sequestered parasites and less cytotoxic T-lymphocytes within the brain, manifesting in a better disease outcome. We present evidence that NR2F6 deficiency renders mice more resistant to experimental cerebral malaria (ECM), confirming a causal and non-redundant role for NR2F6 in the progression of ECM disease. Consequently, pharmacological inhibitors of the NR2F6 pathway could be of use to bolster BBB integrity and protect against CM.
ISSN:2073-4409